The impact of body mass index on laboratory, clinical outcomes and treatment costs in assisted reproduction: a retrospective cohort study

Table 2 Ovarian stimulation protocol characteristics between groups according to BMI

	G1 n = 1940	G2 n = 530	G3 n = 183	p
GnRH protocol (%)
Agonist	15.8	17.4	15.4	0.673^a
Antagonist	84.2	82.6	84.6	0.673^a
Gonadotropins (%)
hMG	36	39.9	43.6 *	0.017^a
FSHr	72.5	70.9	64 *	0.046^a
FSHr +hMG	26.7	31.2	27.4	0.119^a
FSHr +LHr	7.4	6.9	9.1	0.605^a
CFA	9.3*	6.9	4.3	0.024^a
Trigger (%)
hCGr	88.2	91.7	90.1	0.067^a
GnRH agonist	11.8	8.3	9.9	0.067^a

GnRH Gonadotropin releasing hormone, hMG Urinary gonadotropin, FSHr Recombinant Follicle-Stimulating Hormone, LHr Recombinant Luteinizing Hormone, CFA Corifollitropin alfa, hCGr Recombinant Human chorionic gonadotropin
G1. Group 1 BMI ≤ 24.9 kg/m², G2. Group 2 BMI 25–29.9 kg/m², G3. Group 3 BMI ≥ 30 kg/m²
Values presented as n (%). * Different group considering p < 0.05
^aQui-square test and post hoc curve

ISSN: 1472-6874